Alectinib vs Brigatinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline
Alectinib · Alecensa
Marketed by Roche and partners
NCT02075840 · Phase 3 · completed
Participants were randomly assigned to alectinib or the active comparator crizotinib (152 versus 151), but the trial was open-label rather than double-blind. The primary progression-free survival endpoint was met, with alectinib showing a hazard ratio of 0.47 versus crizotinib (p<0.0001), but the lack of blinding limits the overall evidence strength.
Next expected readout: November 2026 · NCT04302025 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 (From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months)): Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019). (met)
Result source: NCT02838420
Brigatinib
Marketed by Takeda Pharmaceutical Company
NCT02737501 · Phase 3 · completed
This was a randomized, open-label active-controlled trial of 275 participants, with progression-free survival assessed by a blinded independent review committee as the primary clinical endpoint. The primary comparison favored brigatinib and was statistically significant, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT04223596 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months (missed)
Result source: NCT03596866
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alectinib | Brigatinib |
|---|---|---|
| PFS, median | 10.9 vs 1.4vs Premetrexed/DocetaxelNCT026043425 other results
| 24.0 vs 11.1vs CrizotinibNCT0273750110 other results
|
| OS, median | 81.1 vs 54.2vs CrizotinibNCT020758403 other results
| 25.9bNCT020945738 other results
|
| ORR | 82.9% vs 75.5%vs CrizotinibNCT020758409 other results
| 74.5% vs 62.3%vs CrizotinibNCT027375016 other results
|
| Duration of response, median | 42.3 vs 11.1vs CrizotinibNCT020758403 other results
| 33.1 vs 13.8vs CrizotinibNCT027375012 other results
|
PFS, median
- Alectinib
- 10.9 vs 1.4vs Premetrexed/DocetaxelNCT02604342
5 other results
- 25.7 vs 10.4 NCT02075840
- 7.1 vs 1.6 NCT02604342
- 8.2 NCT01871805
- 8.4 NCT01871805
- 8.9 NCT01801111
- Brigatinib
- 24.0 vs 11.1vs CrizotinibNCT02737501
10 other results
- 19.3 vs 19.2 NCT03596866
- 16.8 vs 16.6 NCT03596866
- 9.2 NCT02094573
- 15.6 NCT02094573
- 12.6 NCT01449461
- 11 NCT01449461
- 5.4 NCT01449461
- 5.4 NCT01449461
- 5.4 NCT01449461
- 1.8 NCT01449461
OS, median
- Alectinib
- 81.1 vs 54.2vs CrizotinibNCT02075840
3 other results
- 27.8 NCT02604342
- 27.9 NCT01871805
- 29.2 NCT01801111
- Brigatinib
- 25.9bNCT02094573
8 other results
- 40.6 NCT02094573
- 21.3 NCT03535740
- 11.6 NCT01449461
- 17.9 NCT01449461
- 8.3 NCT01449461
- 7.3 NCT01449461
- 7.3 NCT01449461
- 5.3 NCT01449461
ORR
- Alectinib
- 82.9% vs 75.5%vs CrizotinibNCT02075840
9 other results
- 48.1% vs 0% NCT02604342
- 52.2% NCT01871805
- 50.8% NCT01801111
- 44.8% NCT01801111
- 52.9% NCT01871805
- 51.4% NCT01801111
- 50% NCT01801111
- 73.1% NCT01801111
- 57.1% NCT01801111
- Brigatinib
- 74.5% vs 62.3%vs CrizotinibNCT02737501
6 other results
- 45.5% NCT02094573
- 57.3% NCT02094573
- 26.2% NCT03535740
- 51.8% NCT02094573
- 56.4% NCT02094573
- 26.2% NCT03535740
Duration of response, median
- Alectinib
- 42.3 vs 11.1vs CrizotinibNCT02075840
3 other results
- 14.9 NCT01871805
- 13.3 NCT01871805
- 15.2 NCT01801111
- Brigatinib
- 33.1 vs 13.8vs CrizotinibNCT02737501
2 other results
- 12 NCT02094573
- 13.8 NCT02094573
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. Alectinib: 11 of 11 rows · Brigatinib: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alectinib Rows use multiple source trials | Brigatinib Rows use multiple source trials |
|---|---|---|
| CNS ORR responder rate · % of participants No placebo or comparator arm | 58.8% (n=34)a,b,c,d,e NCT01801111 · Phase 1/2 show 1 more dose44.1% (n=34) NCT01801111 · Phase 1/2 | 47.4% (n=19)90 mga,b,c,d,e NCT02094573 · Phase 2 show 3 more doses12.1% (n=33)90 mg NCT02094573 · Phase 2 73.3% (n=15)90 mg - 180 mg NCT02094573 · Phase 2 16.7% (n=36)90 mg - 180 mg NCT02094573 · Phase 2 |
| Disease Control responder rate · % of participants | 82.7% (n=52) vs 25% (n=28) Premetrexed/Docetaxelf,d,e NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 | 85.4% (n=137) vs 86.2% (n=138) Crizotinib90 mg QD/180 QDf,d,e NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 |
| Disease Control responder rate · % of participants No placebo or comparator arm | 66.7% (n=87)600 mg (Fed)b,c,d,e NCT01871805 · Phase 1/2 · registry result, not featured evidence | 81.3% (n=112)90 mga,b,c,d,e NCT02094573 · Phase 2 show 1 more dose86.4% (n=110)90 mg - 180 mg NCT02094573 · Phase 2 |
| Duration of Response time to event · months No placebo or comparator arm | 15.2 monthsb,c,d,e NCT01801111 · Phase 1/2 2 other source trials14.9 months600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence 13.3 months600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | 12 months90 mga,b,c,d,e NCT02094573 · Phase 2 show 1 more dose13.8 months90 mg - 180 mg NCT02094573 · Phase 2 |
| ORR responder rate · % of participants No placebo or comparator arm | 50.8% (n=122)a,b,c,d,e NCT01801111 · Phase 1/2 show 5 more doses44.8% (n=96) NCT01801111 · Phase 1/2 73.1% (n=26) NCT01801111 · Phase 1/2 51.4% (n=138) NCT01801111 · Phase 1/2 50% (n=110) NCT01801111 · Phase 1/2 57.1% (n=28) NCT01801111 · Phase 1/2 | 45.5% (n=112)90 mga,b,c,d,e NCT02094573 · Phase 2 show 3 more doses51.8% (n=112)90 mg NCT02094573 · Phase 2 57.3% (n=110)90 mg - 180 mg NCT02094573 · Phase 2 56.4% (n=110)90 mg - 180 mg NCT02094573 · Phase 2 |
| Overall Survival time to event · months No placebo or comparator arm | 29.2 monthsb,c,d,e NCT01801111 · Phase 1/2 1 other source trial27.9 months600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | 25.9 months90 mga,b,c,d,e NCT02094573 · Phase 2 show 1 more dose40.6 months90 mg - 180 mg NCT02094573 · Phase 2 |
| PFS time to event · months No placebo or comparator arm | 8.9 monthsb,c,d,e NCT01801111 · Phase 1/2 2 other source trials8.2 months600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence 8.4 months600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | 9.2 months90 mga,b,c,d,e NCT02094573 · Phase 2 show 1 more dose15.6 months90 mg - 180 mg NCT02094573 · Phase 2 |
| Dropout rate | n/a: no completion milestoneg NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 4 more resultsn/a: no completion milestone NCT02838420 · Phase 3 · monotherapy 54.4% NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone NCT01801111 · Phase 1/2 —600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | 85.4%90 mg QD/180 QDh NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 show 12 more results97.6% NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone90 mg NCT02094573 · Phase 2 n/a: no completion milestone90 mg - 180 mg NCT02094573 · Phase 2 —90/180 mg NCT03535740 · Phase 2 · registry result, not featured evidence —240 mg NCT03535740 · Phase 2 · registry result, not featured evidence n/a: no completion milestone90 mg/180 mg NCT03410108 · Phase 2 · registry result, not featured evidence n/a: no completion milestone90 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone90 mg QD-180 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone240 mg QD/120 mg BID/300 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone180 mg QD/90 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone120 mg QD/60 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone30 mg QD/60 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%g NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 4 more results— NCT02838420 · Phase 3 · monotherapy — NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 8.7% NCT01801111 · Phase 1/2 —600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | —90 mg QD/180 QDh NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 show 12 more results— NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 3.6%90 mg NCT02094573 · Phase 2 12.7%90 mg - 180 mg NCT02094573 · Phase 2 —90/180 mg NCT03535740 · Phase 2 · registry result, not featured evidence —240 mg NCT03535740 · Phase 2 · registry result, not featured evidence 3.8%90 mg/180 mg NCT03410108 · Phase 2 · registry result, not featured evidence 16.7%90 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 9.4%90 mg QD-180 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 26.7%240 mg QD/120 mg BID/300 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 8.3%180 mg QD/90 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence 11.1%120 mg QD/60 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence 0%30 mg QD/60 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 46.1%g NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 4 more results15.2% NCT02838420 · Phase 3 · monotherapy 26% NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 28.3% NCT01801111 · Phase 1/2 24.1%600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | 41.2%90 mg QD/180 QDh NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 show 12 more results30.4% NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 53.2%90 mg NCT02094573 · Phase 2 62.7%90 mg - 180 mg NCT02094573 · Phase 2 46.6%90/180 mg NCT03535740 · Phase 2 · registry result, not featured evidence 23.1%240 mg NCT03535740 · Phase 2 · registry result, not featured evidence 35.6%90 mg/180 mg NCT03410108 · Phase 2 · registry result, not featured evidence 55.6%90 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 43.8%90 mg QD-180 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 73.3%240 mg QD/120 mg BID/300 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 62.5%180 mg QD/90 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence 55.6%120 mg QD/60 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence 16.7%30 mg QD/60 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | g constipation 40.1% anaemia 27.6% blood bilirubin increased 24.3% NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 4 more resultsaspartate aminotransferase increased 52% blood bilirubin increased 48.8% blood creatine phosphokinase increased 44% NCT02838420 · Phase 3 · monotherapy constipation 20.8% anaemia 15.6% myalgia 14.3% NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 600 mg (Fed) fatigue 41.4% constipation 39.1% headache 28.7% NCT01871805 · Phase 1/2 · registry result, not featured evidence | 90 mg QD/180 QDh diarrhoea 57.4% blood creatine phosphokinase increased 50% cough 36% NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 show 12 more resultsblood creatine phosphokinase increased 73.6% aspartate aminotransferase increased 56.8% alanine aminotransferase increased 47.2% NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 90/180 mg diarrhoea 39.8% blood creatine phosphokinase increased 34% nausea 28.2% NCT03535740 · Phase 2 · registry result, not featured evidence 240 mg diarrhoea 53.8% blood creatine phosphokinase increased 38.5% aspartate aminotransferase increased 23.1% NCT03535740 · Phase 2 · registry result, not featured evidence 90 mg/180 mg blood creatine phosphokinase increased 77.9% hypertension 47.1% diarrhoea 45.2% NCT03410108 · Phase 2 · registry result, not featured evidence 90 mg QD fatigue 50% diarrhoea 44.4% headache 44.4% NCT01449461 · Phase 1/2 · registry result, not featured evidence 90 mg QD-180 mg QD diarrhoea 53.1% fatigue 50% nausea 50% NCT01449461 · Phase 1/2 · registry result, not featured evidence 240 mg QD/120 mg BID/300 mg QD fatigue 80% cough 53.3% diarrhoea 53.3% NCT01449461 · Phase 1/2 · registry result, not featured evidence 180 mg QD/90 mg BID nausea 68.8% diarrhoea 43.8% fatigue 39.6% NCT01449461 · Phase 1/2 · registry result, not featured evidence 120 mg QD/60 mg BID fatigue 50% nausea 50% aspartate aminotransferase increased 38.9% NCT01449461 · Phase 1/2 · registry result, not featured evidence 30 mg QD/60 mg QD abdominal pain 50% nausea 50% electrocardiogram qt prolonged 33.3% NCT01449461 · Phase 1/2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 1/2 versus Phase 2.
- cPopulation context differs: registered conditions differ.
- dTreatment context has not been resolved for both arms.
- eThe assessment timepoint is not available for both results.
- fPopulation context differs: registered conditions differ; prior_therapy differs (experienced versus naive).
- gPopulation comparability has not been reviewed for 3 of these studies.
- hPopulation comparability has not been reviewed for 11 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alectinib
show 1 more result
+ 624 further endpoints in the CSV export.
Brigatinib
show 1 more result
show 3 more results
show 7 more results
show 1 more result
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alectinib's landscape · Brigatinib's landscape